Teachers Retirement System of The State of Kentucky reduced its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 21.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 321,956 shares of the biopharmaceutical company’s stock after selling 86,785 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.30% of Lexicon Pharmaceuticals worth $3,957,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Malaga Cove Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $521,000. Sector Gamma AS increased its stake in shares of Lexicon Pharmaceuticals by 18.4% in the 3rd quarter. Sector Gamma AS now owns 737,453 shares of the biopharmaceutical company’s stock valued at $9,063,000 after buying an additional 114,798 shares during the period. C WorldWide Group Holding A S increased its stake in shares of Lexicon Pharmaceuticals by 49.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 5,353 shares during the period. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $9,420,000. Finally, Wedbush Securities Inc. increased its stake in shares of Lexicon Pharmaceuticals by 28.1% in the 3rd quarter. Wedbush Securities Inc. now owns 112,233 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 24,593 shares during the period.

Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) opened at $9.88 on Tuesday. Lexicon Pharmaceuticals, Inc. has a 12-month low of $8.07 and a 12-month high of $18.00. The company has a current ratio of 1.66, a quick ratio of 1.65 and a debt-to-equity ratio of 1.09.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The business had revenue of $26.94 million for the quarter, compared to analyst estimates of $27.97 million. During the same period last year, the company earned ($0.35) EPS. The firm’s revenue was down 2.8% on a year-over-year basis. equities analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.45 EPS for the current year.

Several research firms have recently commented on LXRX. BidaskClub cut Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. Wedbush restated an “ourperform” rating and issued a $39.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. Cowen Inc restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average price target of $28.75.

In other Lexicon Pharmaceuticals news, insider Lonnel Coats bought 30,000 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, September 15th. The shares were purchased at an average cost of $12.54 per share, for a total transaction of $376,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Public Equities L.P. Invus bought 145,680 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, November 10th. The shares were acquired at an average price of $9.74 per share, for a total transaction of $1,418,923.20. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 945,353 shares of company stock worth $9,304,953. Corporate insiders own 5.77% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/28/teachers-retirement-system-of-the-state-of-kentucky-lowers-stake-in-lexicon-pharmaceuticals-inc-lxrx.html.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.